Cimoxatone
Appearance
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.070.537 |
Chemical and physical data | |
Formula | C19H18N2O4 |
Molar mass | 338.363 g·mol−1 |
| |
(what is this?) (verify) |
Cimoxatone (MD 780515) is a reversible inhibitor of MAO-A (RIMA).[1] It has a significant food interaction–related adverse effect in combination with tyramine.[2] It was never marketed.
Synthesis
The condensation of 4-benzyloxyaniline [6373-46-2] (1) with 1-chloro-3-methoxy-2-propanol [4151-97-7] (2) in ethanol alcohol gave (3); cyclization with diethylcarbonate in toluene in the presence of NaOMe gave 5-(methoxymethyl)-3-(4-phenylmethoxyphenyl)-1,3-oxazolidin-2-one, CID:19781994 (4). Debenzylation gives 3-(4-hydroxyphenyl)-5-(methoxymethyl)-1,3-oxazolidin-2-one [135605-66-2] (5). which is alkylated with 3-cyanobenzyl bromide [28188-41-2] (6) to give cimoxatone (7).
See also
References
- ^ Nair NP, Ahmed SK, Kin NM, West TE (1995). "Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients". Acta Psychiatr Scand Suppl. 386: 28–35. doi:10.1111/j.1600-0447.1995.tb05921.x. PMID 7717092. S2CID 9100689.
- ^ Nair NP, Ahmed SK, Kin NM (November 1993). "Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide". J Psychiatry Neurosci. 18 (5): 214–25. PMC 1188542. PMID 7905288.
- ^ Ancher, J.F.; Cimoxatone. Drugs Fut 1984, 9, 6, 412.
- ^ DE2923295 idem Guy R. Bourgery et al. U.S. patent 4,287,351 (1981 to Delalande S.A.). See for compound 200.